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Three hundred and eighty-eight consecutive patients with AS (age 71+10 years; aortic-jet velocity 5.1+0.6 m/s) and an
indication for aortic valve replacement (AVR) were included. Of these, 290 patients presented with an indication for sur-
gery at their first visit at theHVC and 98 asymptomatic patients who had been enrolled in anHVCmonitoring programme
developed indications for surgery during follow-up. Time to symptom detection was significantly longer in patients that
presented with symptoms at baseline (352+471 days) than in patients followed in the HVC (76+75 days, P, 0.001).
Despite being educated to recognize and promptly report new symptoms, 77 of the 98 patients in the HVC programme
waited until the next scheduled consultation to report them. Severe symptom onset (NYHA or CCS Class ≥III) was pre-
sent in 61% of patients being symptomatic at the initial visit and in 34% of patients in the HVC programme (P, 0.001).
Conclusion Delays in referral and symptom reporting as well as symptom denial are common in patients with AS. These findings
support the concept of risk stratification to identify patients who may benefit from elective surgery. A structured HVC
programme results in the detection of symptoms at an earlier and less severe stage and thus in an optimized timing of
surgery.
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Introduction
Aortic stenosis (AS) is the most frequent heart valve disease requir-
ing surgery and its incidence is further increasing.1 The natural his-
tory of severe AS is characterized by an asymptomatic phase with
increasing left ventricular outflow tract obstruction and left ven-
tricular pressure overload. Asymptomatic patients with severe AS
can be managed according to a ‘watchful waiting strategy’, although
elective surgery can be considered in selected patients after risk
stratification. After the onset of symptoms, the outcome of patients
with severe AS is dismal with conservative management2,3 and aor-
tic valve replacement (AVR) should be performed without delay.4,5
However, from 30 to 50% of patients with an established indication
for AVR are denied such a procedure. Undertreatment of AS is in
part due to delays in symptom recognition and also late referral
for intervention. Although the potential role of heart valve clinics
(HVCs) for the management of patients with valvular heart disease
(VHD) is increasingly recognized,6,7 their clinical impact has not yet
been evaluated.
The present study sought to evaluate the role of an HVC follow-
up programme for the management of patients with severe AS and
to evaluate its potential to reduce delays in symptom recognition
and reporting and on the severity of symptoms at presentation.
Methods
Patient population
Consecutive patients who were assessed in the outpatient clinic for
VHD at Medical University of Vienna between 2000 and 2010 who
had an indication for AVR based on current practice guidelines due to
severe AS defined by a peak aortic jet velocity ≥4.0 m/s and an aortic
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valve area ≤1.0 cm2 were prospectively included into the study when
they had no additional haemodynamically significant valve lesions (mod-
erate or severe). Patients with low-flow, low-gradient AS were
excluded.
According to these criteria, 388 patients (age 71+10 years; 198 fe-
male; average peak aortic velocity 5.1+ 0.6 m/s) were included. The
majority of these patients were referred from outpatient care specialist
in internal medicine and general cardiologists. At their initial visit, 290 of
these patients already had an indication for AVR, while 98 patients were
previously asymptomatic and had been enrolled in an HVC follow-up
programme comprising 6 monthly clinical and echocardiographic exam-
inations until they reached criteria for surgery. These latter patients had
been educated to promptly report symptoms after their onset.
According to the purely observational study design, written informed
consent was not demanded. The study protocol was approved by the
ethics committee of the Medical University of Vienna.
Clinical data
The following clinical data were collected at study entry: age, gender,
history of hypercholesterolaemia (total cholesterol .200 mg/dL or pa-
tient under lipid-lowering therapy), diabetes mellitus, arterial hyperten-
sion (on the basis of the average of repeated measurements: blood
pressure.140/90 mmHg) and coronary artery disease (history of myo-
cardial infarction, angioplasty, coronary artery bypass grafting, or angio-
graphically documented coronary artery stenosis).
Echocardiographic data
All patients underwent a comprehensive echocardiographic examin-
ation on the basis of a standardized examination protocol including
M-Mode, 2D echocardiography, conventional, and colour Doppler by
an experienced echocardiographer using commercially available ultra-
sound systems. Multiple transducer positions were used to record
peak aortic jet velocities and aortic valve area was calculated using the
continuity equation.8
The degree of aortic valve calcification was scored according to the
following previously described criteria9: (i) no calcification, (ii) mild cal-
cification (isolated, small spots), (iii) moderate calcification (multiple big-
ger spots), and (iv) heavy calcification (extensive thickening/calcification
of all cusps).
Valve clinic programme and follow-up
Patients were followed prospectively. Patients that were initially asymp-
tomatic had been followed at 6 monthly intervals in the HVC until sur-
gical criteria according to the prevailing guidelines4,5 at the moment
were reached. At each visit a thorough medical history was taken by a
physician experienced in the management of patients with VHD with a
specific focus on inquiring the onset of AS-related symptoms and deter-
mining the duration of their onset. In addition to a comprehensive trans-
thoracic echocardiogram, patients underwent a physical examination,
blood testing, blood pressure measurement, and a 12-lead electrocar-
diogram. Exercise testing was performed in selected patients when
doubts existed whether they were truly asymptomatic. Asymptomatic
patients were instructed to recognize symptoms related to AS and to
report any symptom onset without delay. In order to provide easy ac-
cess to the HVC, symptomatic patients could schedule appointments via
telephone every working day during office hours or present themselves
directly at the HVC where they would be examined without delays.
Patients developing an indication for surgery were immediately re-
ferred to AVR and underwent a systematic preoperative work-up (in-
cluding coronary angiography). Patients refusing surgery despite being
informed about the unfavourable outcome of symptomatic severe AS
were encouraged to reconsider their decision and were invited to fur-
ther follow-up exams.
Patients who underwent surgery had a postoperative follow-up visit
in the HVC to assess the surgical outcome. Further postoperative
follow-up exams in the HVC were scheduled at extended intervals, de-
pending on surgical and clinical outcomes. For the completion of post-
operative follow-up information, additional follow-up information was
obtained from interviews with the patients, their relatives and their phy-
sicians, and the review of medical records. Deaths were classified as
non-cardiac or cardiac. The overall survival including perioperative
and late deaths after AVR was assessed.
After each visit in the valve clinic patients were sent a comprehensive
report including the findings obtained during that visit, recommenda-
tions given by the valve clinic based on these findings and dates for fu-
ture appointments.
Statistical analysis
Quantitative variables are described as mean+ standard deviation.
Survival data are summarized by means of Kaplan–Meier functions.
Postoperative survival was analysed using the Kaplan–Meier method.
The effect of different variables (age, gender, hypercholesteraemia,
diabetes mellitus, arterial hypertension, coronary artery disease, aortic
valve jet velocity at entry, and severity of symptoms) on survival was
analysed by means of a multiple Cox proportional hazard model and
hazard ratios (HRs) as well as 95% confidence intervals (CIs) are re-
ported. For comparing themeans of two independent samples, Student’s
t-test was used. The x2 test was used to compare proportions between
two independent samples. A P-value of ,0.05 was considered to indi-
cate statistical significance.
Results
Three hundred and eighty-eight patients were included in the study.
Clinical and echocardiographic baseline characteristics of the pa-
tients in both groups were comparable and are depicted in Table 1.
Follow-up information was complete for all patients when the in-
dication for surgery was established. Postoperative follow-up was
complete for 377 patients (97.2%). After successful AVR, 10 patients
were lost to follow-up. In addition, one patient who initially
presented with symptoms but refused surgery was also lost to
follow-up.
Patients that had been enrolled in the
HVC follow-up programme
These 98 patients had been asymptomatic at their first visit at the
HVC and had been enrolled in a regular follow-up programme
with periodic visits to the HVC.
Delays in symptom reporting
The interval between the patient’s perception of symptom
onset and the reporting of these symptoms was 76+ 75 days
(Figure 1 Q3A). Although all patients in the HVC follow-up programme
were educated to recognize symptoms related to AS and instructed
to promptly report them, only 21 of these 98 patients reported the
onset of symptoms on their own initiative before their next sched-
uled exam with a delay in symptom reporting of 21+26 days. The
remaining 77 patients waited for the next scheduled visit to report
their symptoms with a delay in symptom reporting of 91+ 77 days
(P, 0.001; Figure 1B).
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Severity of symptoms at initial reporting
A severe onset of symptoms (defined as an NYHA or CCS Class
≥III) was observed in 34% of patients enrolled in the follow-up pro-
gramme. No differences in age (69+ 9 and 70+ 9 years; P ¼ 0.75)
and gender (45 and 42%; P ¼ 0.71) were observed among patients
with severe or mild symptom onset (Table 2).
Indications for aortic valve replacement
Surgery was indicated for the following reasons: 85 developments
of symptoms [dyspnoea or chest pain in all patients, additional syn-
cope in 9 patients (9%)]; 8 significant aortic valve calcification and
rapid hemodynamic progression; 2 reduced left ventricular systolic
function; 2 prior to major non-cardiac surgery; and 1 positive exer-
cise test.
Patients presenting with an indication for
surgery at their initial visit
Two hundred and ninety patients presented with symptoms when
they first presented at the HVC. All of these patients thus already
had an indication for surgery at presentation. Most of these patients
were referred from an outpatient care setting by specialists in in-
ternal medicine and general cardiologists.
Delays in symptom reporting
The interval between the onset of symptoms perceived by the pa-
tient and the reporting of these symptoms was 352+471 days.
This interval was significantly longer than in patients that were en-
rolled in the HVC follow-up programme (P, 0.001; Figure 1A).
Severity of symptoms at initial reporting
Severe symptom onset (defined as an NYHA or CCS Class ≥III)
was observed in 61% of the patients. Patients presenting with severe
symptoms (NYHAClass ≥III) were older (73+9 vs. 69+10 years;
P ¼ 0.006) and more likely to be women (64 vs. 38%; P, 0.0001)
than those presenting with mild symptoms (Table 2).
In comparison, patients enrolled in an HVC programme were re-
ferred to surgery with significantly less advanced symptoms when
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Table 1 Baseline patient characteristics according to whether they presented with symptoms at the first visit or were
enrolled in a heart valve clinic follow-up programme
All patients Symptomatic at initial visit Enrolled in HVC programme P-value
n 388 290 98
Gender (female), n (%) 198 (51) 156 (54) 42 (43) 0.06
Age (years) 71+10 71+10 70+9 0.13
Peak aortic jet velocity (m/s) 5.1+0.6 5.1+0.6 5.1+0.7 0.88
Aortic mean gradient (mmHg) 67.2+7.5 67.3+17.2 66.8+18.5 0.79
Aortic valve area (cm2) 0.6+0.2 0.6+0.2 0.7+0.2 0.11
Indexed aortic valve area (cm2/m2) 0.33+0.09 0.33+0.01 0.35+0.09 0.06
Coronary artery disease, n (%) 131 (34) 99 (34) 32 (33) 0.79
Hypertension, n (%) 290 (75) 211 (73) 79 (81) 0.11
Diabetes mellitus, n (%) 89 (23) 66 (23) 23 (23) 0.89
Hypercholesterolemia 156 (40) 117 (40) 39 (40) 0.92
HVC, heart valve clinic.
Figure 1 (A) Delay in symptom reporting. Time to symptom re-
porting in patients enrolled in a heart valve clinic follow-up pro-
gramme when compared with patients being addressed with
symptoms at their first visit to the heart valve clinic. (B) Delay in
symptom reporting in patients enrolled in a heart valve clinic.
Time to symptom reporting in patients enrolled in a heart valve
clinic follow-up programme that reported their symptoms at the
next scheduled follow-up exam only, when compared with pa-
tients enrolled in a heart valve clinic follow-up programmewho re-
ported their symptoms before the next scheduled visit.
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compared with patients presenting with symptoms at their first visit
(P, 0.0001) (Figure 2).
Indications for aortic valve replacement
The indication for AVR was due to manifest symptoms in all but two
patients [dyspnoea or chest pain in 245 patients (84%), dyspnoea or
chest pain and syncope in 34 patients (12%), syncope only in 9 pa-
tients (3%)]. In one patient, the symptomatic status was unclear (the
patient had previously experienced syncope; however, during med-
ical work-up, a meningioma was detected as well) and an exercise
test unmasked dyspnoea at low-level exercise. In another patient
that was scheduled for major orthopaedic surgery, AS was detected
in the preoperative workup and a decrease in the physical capacity
was noted despite a reduced mobility of the patient.
Patients refusing surgery
Surgery was refused by 27 of the 388 patients. Six of these had
been enrolled in the HVC follow-up programme. Fifteen of the
27 (55%) patients changed their mind after initially refusing surgery
and agreed to have surgery with a mean delay of 412 days and after
having been invited for a mean of 1.5 additional follow-up exams.
Three of the 15 patients contacted the HVC on their own initiative
without the need for additional follow-up exams. One patient
eventually decided to undergo surgery after eight additional
follow-up exams.
In addition, two patients who were found not to be suitable
candidates for surgery in the pre-transcatheter aortic valve im-
plantation (TAVI) era died from heart failure within 2 years of
symptom onset.
Mortality on thewaiting list and in patients
refusing surgery
Three deaths occurred in patients awaiting surgery (all acute heart
failure, preserved left ventricular function at the last echocardio-
graphic exam). One patient who had a moderately reduced left ven-
tricular function needed in-hospital cardiopulmonary resuscitation
for bradyasystole during the stay in which AVR was scheduled and
also took place. All four of these patients were symptomatic at their
first visit in our HVC (two in NYHAClass II and two in NYHAClass
III). In addition, eight patients who had refused surgery despite the
development of progressive symptoms died of acute heart failure
(4), myocardial infarction (3), or sudden death (1). Seven of these
patients presented with an indication for surgery at their first visit
in the HVC.
Perioperative and late mortality
A total of 371 patients underwent AVR. Three hundred seventeen
patients received a biological prosthesis (including 4 TAVI), and 53
patients received a mechanical valve prosthesis. A Ross procedure
was performed in one patient. Ninety-two patients required con-
comitant aortocoronary bypass surgery. In total, 95 of the operated
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 2 Baseline patient characteristics according to severity of symptom onset
Variable Symptomatic at initial visit Enrolled in an HVC follow-up program
NYHA ≤II NYHA ≥III P-value NYHA ≤II NYHA ≥III P-value
Gender (female), n (%) 42 (38) 114 (64) ,0.001 27 (42) 15 (45) 0.71
Age (years) 69+10 73+9 0.006 70+9 69+9 0.75
Peak aortic jet velocity (m/s) 5.1+0.6 5.1+0.6 0.69 5.1+0.6 5.0+0.7 0.69
Aortic mean gradient (mmHg) 66.3+16.5 67.9+17.6 0.44 68.1+18.2 64.2+19.1 0.34
Aortic valve area (cm2) 0.7+0.2 0.6+0.2 0.05 0.6+0.2 0.7+0.2 0.39
Indexed aortic valve area (cm2/m2) 0.34+0.08 0.32+0.08 0.08 0.35+0.09 0.35+0.09 0.76
Coronary artery disease, n (%) 46 (41) 53 (30) 0.05 18 (28) 14 (42) 0.15
Hypertension, n (%) 74 (66) 137 (77) 0.04 49 (75) 30 (91) 0.05
Diabetes mellitus, n (%) 20 (18) 46 (26) 0.11 14 (22) 9 (27) 0.53
Hypercholesterolaemia, n (%) 49 (44) 68 (38) 0.35 25 (38) 14 (42) 0.71
HVC, heart valve clinic; NYHA, New York Heart Association Class.
Figure 2 Severity of symptom onset. Severity of symptom onset
in patients enrolled in a heart valve clinic follow-up programme
when compared with patients that presented with symptoms at
their initial visit at the heart valve clinic.
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patients died during follow-up. There were 15 perioperative (within
30 days of surgery) deaths (12 in patients with an initial indication for
surgery). Eight deaths (six in patients with an initial indication for
surgery) occurred in the early postoperative period (1–3 months
after surgery) for the following reasons: one aspiration pneumonia
after tracheostomy; one acute respiratory distress syndrome; one
systemic inflammatory response syndrome (SIRS); two sepsis; two
sepsis after sternal infection; and one cardiac decompensation.
Seventy-two deaths were observed during late follow-up (32 car-
diac deaths, 37 non-cardiac deaths, and 3 unknown).
The actuarial probability of survival (including perioperative and
late deaths after AVR) was 92% at 1 year, 88% at 2 years, 86% at
3 years, and 75% at 4 years.
Prognostic factors associated with
postoperative survival
The severity of preoperative symptoms was associated with post-
operative survival. Survival rates for patients with mild symptoms
(NYHA or CCS ≤II) were 94+ 2, 90+ 3, 87+ 3, and 74+ 5%
at 1, 2, 3, and 6 years, whereas survival rates for patients with severe
symptoms (NYHA or CCS ≥III) were 90+ 2, 86+ 3, 84+ 3, and
62+ 5% at 1, 2, 3, and 6 years, respectively (P ¼ 0.008) (Figure 3).
Postoperative all-cause mortality was not different between the
two groups (P ¼ 0.95).
By multivariable analysis, male sex [P ¼ 0.03, HR 1.68 (CI 1.03–
2.72)], age at baseline [P, 0.0001, HR 1.08 (CI 1.05–1.12)], severe
preoperative symptoms [P ¼ 0.04, HR 1.60 (CI 1.00–2.61)], and
diabetes [P ¼ 0.008, HR 2.0 (CI 1.20–3.26)] were associated with
a higher postoperative mortality.
Discussion
Importance of specialized care
for patients with VHD
The potential benefits of HVCs are being increasingly recognized.6,7
In particular, patients with severe AS can be safely managed accord-
ing to a watchful waiting strategy9 even in the presence of associated
aortic regurgitation.10 Nevertheless, patients with VHD are not al-
ways managed in an appropriate setting. Information and education
of these patients are often suboptimal and many do not receive a
timely diagnosis and optimal care according to current best practice
guidelines,11 resulting in a delayed referral for surgery. An analysis of
the STS database confirmed that 38 and 10% of patients undergoing
AVR in 2006 presented in NYHA Classes III and IV, respectively.12
However, an improvement was achieved in comparison with 1997
when 46 and 19% of patients presented in NYHA Classes III and IV,
respectively.12 Data from the Euro Heart Survey show that 216 of
284 patients with AS presented with severe symptoms and that sur-
gery was denied in 33% of symptomatic elderly patients with severe
AS.13 Therefore, without appropriate care, patients with VHD are
likely to have a poor outcome characterized by high morbidity
and mortality caused in part by late referral but also by denial of sur-
gery. With optimized timing of intervention, surgery is an effective
treatment that improves both symptoms and survival.9,14 Further-
more, the threshold to refer a high-risk patient to treatment has re-
cently been lowered by the advent of TAVI.
Indeed, an appropriate setting is essential for a watchful waiting
approach,9,15,16 which is recommended by current guidelines in
asymptomatic patients with severe VHD in the absence of specific
risk factors that may warrant earlier intervention.4,5
Severity of symptom onset
The severity of preoperative symptoms is a marker of increased op-
erative risk.14 Ideally, patients should be referred for surgery with
the onset of mild symptoms. Severe symptom onset, defined as
an NYHA or CCS Class ≥III, was observed in 34% of patients
that had regular follow-up exams in the HVC programme and in
61% of patients presenting with symptoms at the first visit. Patients
being operated with severe symptoms had significantly worse sur-
vival rates when compared with patients being operated with mild
symptoms.
Women and elderly patients were at particular risk to present
with severe symptoms at their first visit in the HVC, indicating
that these patient groups are at an even more accentuated risk of
referral delays. However, in patients enrolled in the HVC follow-up
programme, no differences in age or gender were observed be-
tween patients with mild or severe symptom onset, indicating that
state-of-the-art management avoids the potential discrimination of
these populations.
Delays in symptom reporting
Considering an annual mortality rate of #30% for patients with se-
vere symptomatic AS,3,17 an individual patient’s risk can effectively
be lowered by early recognition of symptoms and consequently a
timely referral to valve intervention. This is the first study to specif-
ically assess the benefits of an HVC—based follow-up programme
Figure 3 Postoperative survival according to severity of symp-
toms. Kaplan–Meier postoperative survival for patients in
NYHA Classes I and II (red line) when compared with patients
in NYHA Classes III and IV (blue line).
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for the management of patients with AS. Patients being included in a
follow-up programme had a significantly shorter duration of symp-
toms and presented in an advanced symptomatic stage. In contrast,
patients being addressed with symptoms at their first visit to the
HVC presented with long delays between symptom onset and re-
ferral, amounting to 1 year on average.
In addition, a mortality risk on the waiting list for surgery of #15%
per year can be assumed.18 This risk is illustrated by the fact that in
the present study, three patients died while waiting for surgery and
another patient received successful cardiopulmonary resuscitation
while being admitted for surgery—all of these four patients pre-
sented with an indication for surgery at baseline. In this regard, en-
rolment in an HVC programme in a specialized cardiovascular
centre might avert the risk of unnecessary delays in referral for sur-
gery once that an indication is present.
Importance of risk stratification
Only 21% of the patients enrolled in the HVC follow-up programme
reported an onset of symptoms before the next scheduled visit. The
fact that 79% of the patients waited for the next visit to report their
symptoms might be explained by denial of symptoms, the attribu-
tion of mild symptoms to ‘aging’ or ‘lack of exercise’ rather than
AS as well as lacking perception of early symptoms by individuals
with more sedentary lifestyles. The reason for a relatively short
interval between symptom onset and reporting in these latter pa-
tients is only explained by the tightly scheduled follow-up exams. Al-
though it is important to educate the patients to recognize the
possible symptoms that may occur, such a measure alone remains
insufficient and close monitoring is warranted. Even when enrolled
in a follow-up programme, 34% of the patients presented with se-
vere symptoms (NYHA ≥III). These findings highlight the import-
ance of risk stratification,19 to identify patients who are likely to
develop symptoms in the near future and in whom elective surgery
should be considered.9,20,21
Importance of follow-up visits after
patient refusal of surgery
After being invited to additional follow-up exams, 15 (55%) of the 27
patients who initially refused surgery would later accept an AVR.
While most of the patients reconsidered their decision after one
to three additional follow-up exams, one patient changed her
mind after as many as eight follow-up exams. A strategy of repetitive
follow-up exams and continuous patient education is thus beneficial
even in patients who initially refuse surgery despite a clear indication
for surgery and should be offered systematically.
Study limitations
The present study was not specifically designed and powered to de-
tect differences in postoperative survival between the two groups. It
is therefore limited in this regard by the number of patients under-
going surgery in each of the groups.
Exercise testing was performed according to clinical judgment
and not systematically.
The assessment of early symptoms in AS and the precise evalu-
ation of symptom durationmight be clinically challenging and subject
to interobserver variability.
Until recently, no standards for the organization and structure of
HVCs had been defined and the results reported in this study were
obtained in one single centre.
Conclusion
Delays in referral and symptom reporting as well as symptom denial
are common in patients with AS. These findings support the con-
cept of risk stratification to identify patients who may benefit
from elective surgery. A structured HVC programme results in
the detection of symptoms at an earlier and less severe stage and
thus in an optimized timing of surgery. The dissemination of such
centres of excellence should therefore be promoted Q4.
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